Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2013 / Cilt: 39 - Sayı: 3

The value of the NMP22 test for superficial bladder cancer diagnosis and follow-up

Yüzeyel mesane tümörlü hastaların tanı ve takibinde NMP22 testinin değerliliği

Pages
137–142
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The sensitivity, specificity, positive predictive value, negative predictive value and positive likelihood ratio (LR+) of the cytology examination were 25%, 97%, 75%, 80% and 9.25, respectively.Conclusion: The NMP22 test can be used as an adjunctive tool for the detection of bladder cancer, but its diagnostic performance is limited in surveillance when used alone or in combination with a cytology examination.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, we investigated the efficacy of nuclear matrix protein 22 (NMP22) in the diagnosis and surveillance of bladder cancer.
📊
Key Findings & Data:A routine cytologic examination and NMP22 test were performed on the voided urine sample that was provided before the cystoscopy.
💡
Conclusion & Impact:The sensitivity, specificity, positive predictive value, negative predictive value and positive likelihood ratio (LR+) of the cytology examination were 25%, 97%, 75%, 80% and 9.25, respectively.Conclusion: The NMP22 test can be used as an adjunctive tool for the detection of bladder cancer, but its diagnostic performance is limited in surveillance when used alone or in combination with a cytology examination.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, we investigated the efficacy of nuclear matrix protein 22 (NMP22) in the diagnosis and surveillance of bladder cancer. Material and methods: Patients with a complaint of hematuria or who required cystoscopic control of prov- en bladder cancer were prospectively enrolled in this study. A routine cytologic examination and NMP22 test were performed on the voided urine sample that was provided before the cystoscopy. The patients who had been diagnosed with bladder cancer were categorized according to stage, grade, number, measure and risk, and the diagnostic performance of the NMP22 test and the cytology test, alone or in combination, were evaluated separately using ROC curves in the diagnosis and surveillance groups. Results: There were 87 patients (of the 136 total patients) who were investigated because of hematuria. The sensitivity, specificity, positive predictive value, negative predictive value and positive likelihood ratio (LR+) of the NMP22 test were 70%, 80%, 68%, 81% and 3.42, respectively. The sensitivity, specificity, positive pre- dictive value, negative predictive value and positive likelihood ratio (LR+) of the cytology examination were 27%, 96%, 82%, 68% and 7.36, respectively. There were 49 patients in the group that had been diagnosed with bladder cancer. The sensitivity, specificity, positive predictive value, negative predictive value and positive likelihood ratio (LR+) of the NMP22 test in these patients were 33%, 76%, 31%, 78% and 1.37, respectively. The sensitivity, specificity, positive predictive value, negative predictive value and positive likelihood ratio (LR+) of the cytology examination were 25%, 97%, 75%, 80% and 9.25, respectively.Conclusion: The NMP22 test can be used as an adjunctive tool for the detection of bladder cancer, but its diagnostic performance is limited in surveillance when used alone or in combination with a cytology examination.

Özet

Amaç: Bu çalışmada nükleer matriks protein 22 (NMP22) testinin teşhiste ve yüzeyel mesane tümörü tanılı hastaların takibindeki etkinliği araştırıldı. Gereç ve yöntemler: Hematüri saptanmış veya mesane tümörü tanısı olup kontrol amaçlı başvurmuş olan hastalar prospektif olarak çalışmaya dahil edildi. Sistoskopi öncesi alınan idrar örneği ile sitoloji ve NMP22 testi çalışıldı. Mesane kanseri tanısı alan hastalar evre, derece, sayı, boyut ve risk açısından kategorize edi- lip NMP22 testi ile sitolojinin her biri için ROC eğrileri elde edildi ve iki testin tek başına veya kombine tanısal performans değerleri tanı ve takip için ayrı ayrı araştırıldı. Bulgular: Hematüri nedeni ile araştırılan grupta toplam 87 hasta olup NMP22 testinin duyarlılık oranı %70, özgüllük oranı %80, pozitif kestirim değeri %68, negatif kestirim değeri %81 ve pozitif test sonucu- nun olasılık (LR+) oranı 3,42 olarak bulundu. Sitolojinin duyarlılık oranı %27, özgüllük oranı %96, pozitif kestirim değeri %82, negatif kestirim değeri %68 ve pozitif test sonucunun olasılık (LR+) oranı 7,36 olarak bulundu. Mesane tümörü tanısı olup takip edilen grupta toplam 49 hasta olup NMP22 testinin duyarlılık oranı %33, özgüllük oranı %76, pozitif kestirim değeri %31, negatif kestirim değeri %78 ve pozitif test sonucunun olasılık (LR+) oranı 1,37 olarak saptandı. Sitolojinin duyarlılık oranı %25, özgüllük oranı %97, pozitif kestirim değeri %75, negatif kestirim değeri %80 ve pozitif test sonucunun olasılık (LR+) oranı 9,25 olarak saptandı. Sonuç: NMP22 testi, mesane kanseri tanısında sistoskopiye yardımcı olarak kullanılabilir. Mesane kanseri tanılı hastaların takibinde tek başına ya da idrar sitolojisi ile kombinasyonunun tanı koydurucu gücü sınırlıdır.

🔖

Cite This Article

DOĞAN, C., PELİT, E. S., YILDIRIM, A., ZEMHERİ, I. E., ÇANAKCI, C., BAŞOK, E. K., ÇAŞKURLU, T. (2013). The value of the NMP22 test for superficial bladder cancer diagnosis and follow-up. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 39 - Sayı: 3, 137–142. https://ajindex.com/articles/328010

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Zorlu F, Eser SY, Fidaner C. İzmir ilinde ürogenital kanserlerin insidans hızları. Üroonkoloji Bülteni 2004;1:2-9
  2. National Comprehensive Cancer Network. Available at: http:// www.nccn.org/professionals/physicians_gls/PDF/bladder.pdf. Ac- cessed December 23, 2005
  3. Frimberger D, Zaak D, Hofstetter A. Endoscopic fluorescence di- agnosis and laser treatment of transitional cell carcinoma of the bladder. Semin Urol Oncol 2000;18:264-72
  4. Brown FM. Urine cytology. Is it stil the gold standart for scree- ning? Urol Clin North Am 2000;27:25-37. [CrossRef] 5. Tritschler S, Scharf S, Karl A, Tilki D, Knuechel R, Hartmann A, et al. Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis. Eur Urol 2007;51:403-8. [CrossRef] 6. American Joint Committee on Cancer. Cancer Staging Manual, 5th Edition. 1997; Philadelphia, Pa: American Joint Committee on Cancer
  5. Mostofi FK, Davis CJ, Sesterhenn IA. WHO histologic typing of urinary bladder tumors. 1999; Berlin: Springer Verlag; 1999. p. 2-56. [CrossRef] 8. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point-of-care proteo- mic assay. JAMA 2005;293:810-6. [CrossRef] 9. Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, et al. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int 2012;110:699-708
  6. Sarılar Ö, Mender E, Kabay Ş, Binbay M, Berberoğlu Y, Müslü- manoğlu AY. Nükleer matriks proteinin (NMP22) mesane kanseri teşhisiyle, tümörün evresi, grade, tümör büyüklüğü ve sayısı ile olan ilişkisi ve bu bulguların sitoloji ile karşılaştırılması. Türk Üroloji Dergisi 2002;28:397-400
  7. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabi- an V, et al. Surveillance for recurrent bladder cancer using a point- of-care proteomic assay. JAMA 2006;295:299-305. [CrossRef] 12. Kumar A, Kumar R, Gupta NP. Comparision of NMP22 BladderC- hek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol 2006;36:172-5. [CrossRef] 13. Schlake A, Crispen PL, Cap AP, Atkinson T, Davenport D, Preston DM. NMP-22, urinary cytology, and cystoscopy: a 1 year compa- rison study. Can J Urol 2012;19:6345-50
  8. Çal Ç, Erdoğan Ö, Kosova B, Ekren F, Veral A, Delibaş M. İd- rar NMP22 testi, telomeraz testi ve sitolojisinin tek veya birlikte kullanımları yüzeyel mesane tümörü nükslerinin ta